Maintain TMO at neutral weight; defer additions until pullback to $651–$663 or breakout above $682.98 with volume, hard stop at 10 EMA $663.53
Three-analyst consensus maintains TMO at neutral weight with no additions at $679.61; structural thesis intact (Q2 revenue +10.5% YoY, EPS +9.3% YoY, golden cross at $590/$535, 80% recurring consumables base, $4B cash, $8.5B TTM operating cash flow, $1B+ quarterly buyback, M&A synergies ahead of P&L), but entry point stretched with RSI 73.83, MACD histogram deceleration (+3.00 vs +4.75), and asymmetric risk (2–7% upside vs 4–10% downside); prior decision history binding — 9/25 reflection confirmed WC-driven FCF compression is weakest fundamental deterioration category priced through by quality-compounder multiples; 9/1–9/2 Underweight trim errors destroyed alpha harvesting into vertical extensions; neutral calibration honors setup asymmetry without forcing exit on defensive compounder with intact golden cross, active buyback, and forward EPS optionality not yet in P&L; scaled add framework of 1/3 on pullback, 1/3 on breakout, 1/3 reserved post-Q3 captures breakout optionality without forcing capital into stretched entry four weeks before binary catalyst.
| Position | Action |
|---|---|
| Pullback to $651–$663 zone with RSI resetting toward 55–60 on declining volume | Add 1/3 position |
| Confirmed daily close above $682.98 on volume ≥3M shares | Add 1/3 position |
| Post-Q3 2026 earnings confirmation (late October) | Add final 1/3 position reserved |
The bear's use of a cyclical-trader's framework on what is fundamentally a secular compounder is producing the wrong conclusion; TMO's golden cross, volume-confirmed accumulation, accelerating earnings, and underappreciated M&A synergy pipeline make the risk/reward at 679.61 favorable with a BUY target of $730.
| Indicator | Value | Signal |
|---|---|---|
| RSI | 73.83 | bearish |
| MACD | 20.95 | neutral |
| MACD Signal | 17.96 | neutral |
| MACD Histogram | +3.00 | bearish |
| 50 SMA | 609.89 | bullish |
| 200 SMA | 540.44 | bullish |
| 10 EMA | 663.53 | bullish |
| VWMA | 651.06 | bullish |
| Bollinger Middle Band | 638.31 | neutral |
| Bollinger Upper Band | 698.22 | bearish |
| Bollinger Lower Band | 578.39 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed daily close above $682.98 on volume ≥3M shares
Then: Add 1/3 position
EV: +7.4% (target $730 vs. current $679.61) · concedes: PEG of 2.0 is above 1 (though appropriate for quality compounder); Net Debt/EBITDA at 3.3x is elevated vs. 2.5x historical norm; 30-year yields at multi-decade highs compress multiples at the margin; Waiting for pullback to 10 EMA at 663 or VWMA at 651 may happen
The bull's argument is anchored in past performance and does not justify initiating new exposure at TMO's most overbought reading of 2026; the entry point is wrong and risk/reward is asymmetric to the downside.
· concedes: TMO's structural thesis is intact (market position, switching costs, recurring revenue); The trend is too strong to fight—no short recommended; The bull knows the company well and technicals check out for past performance; Q2 2026's +10.5% YoY growth is encouraging; Beta of 0.85 provides some downside protection in market selloffs
→ vs conservative: Stop at 10 EMA around 663 misses asymmetric opportunity - breakout above 682.98 offers 7% upside versus 4.2% downside, and waiting for 651 may never materialize after 56% run from May lows
→ vs conservative: RSI 73.83 overbought fear is lazy analysis - RSI can remain elevated for extended periods in structural breakouts, and here it confirms strength alongside golden cross and accumulation
→ vs conservative: MACD divergence argument overweighted - histogram at +3.00 still positive, and momentum cooling after strong rally is healthy consolidation, not distribution
→ vs neutral: 30-year Treasury highs and zero rate cut probability are manageable headwinds for defensive compounder - TMO's beta 0.854, fortress balance sheet, and $8.5 billion operating cash flow attract quality rotation
| bullish |
| ATR | 15.60 | neutral |
Support: 663.53 · 651.06 · 609.89 · 578.39 · 540.44 | Resistance: 682.98 · 698.22 · 700
The primary trend remains unambiguously bullish with price holding above all moving averages in a perfect stack (Price > 10 EMA > 50 SMA > 200 SMA) and the golden cross intact. However, the setup shows classic late-stage rally fatigue: RSI at 73.83 represents the highest reading of 2026, MACD histogram is barely positive (+3.00) despite price making new highs (momentum divergence), and price is only 2.7% below the Bollinger upper band at 698.22. The composite signal is a late-stage bull trend warranting a HOLD rating — existing positions should be maintained with trailing stops at 10 EMA (663.53) or VWMA (651.06), while new entries should await either a pullback to dynamic support or a confirmed breakout above 698-700 for better risk/reward.
Market Cap
$251.28 Billion
P/E (TTM)
36.6x
Forward P/E
24.7x
PEG Ratio
2.02
P/B
4.77
EV/EBITDA (est.)
~22.5x
Dividend Yield
0.28%
FCF Yield
~2.5%
2025 Revenue
$44,557M
2025 Gross Profit
$18,239M
2025 Operating Income
$8,110M
2025 Net Income
$6,704M
2025 Diluted EPS
$17.74
2025 Free Cash Flow
$6,293M
EBITDA (TTM)
$11.74B
Q2 2026 Revenue
$11,994M
Q2 2026 Net Income
$1,736M
Q2 2026 Diluted EPS
$4.68
Total Assets (Q2 2026)
$113,174M
Total Equity (Q2 2026)
$52,680M
Total Debt (Q2 2026)
$42,549M
Net Debt (Q2 2026)
$38,485M
Cash & Equivalents (Q2 2026)
$4,064M
Goodwill & Intangibles (Q2 2026)
$73,438M
Current Ratio (Q2 2026)
1.55
Debt/Equity
80.6%
Book Value Per Share
$142.47
Tangible Book Value
-$20.76B
Gross Margin (TTM)
41.0%
Operating Margin (TTM)
18.75%
Net Margin (TTM)
15.04%
ROE
13.5%
ROA
5.1%
Beta
0.854
52-Week Range
$435.27 – $682.98
50-Day Moving Avg
$607.18
200-Day Moving Avg
$540.80
Forward EPS (Consensus)
$27.54
Buybacks (2025)
$3.0B
Dividends (2025)
$636M
Strengths
Concerns
Thermo Fisher Scientific (TMO) is the world's largest pure-play life sciences tools and diagnostics company with ~$251B market cap and $44.6B in annual revenue. The company delivers strong profitability (41% gross margin, 15% net margin, $11.74B EBITDA) with best-in-class ~100% FCF conversion, driven by its highly recurring revenue model (~80% consumables/services/reagents). Despite premium valuation (P/E 36.6x, PEG 2.0) and elevated post-M&A leverage (Net Debt/EBITDA ~3.3x), TMO offers defensive characteristics (Beta 0.85), consistent capital return ($3B+ annual buybacks), and multiple near-term catalysts from recent acquisitions in proteomics and filtration, warranting a HOLD rating for long-term investors while seeking opportunistic entries on weakness toward the 200-day MA (~$540).
Macro: The dominant macro theme is rising long-end Treasury yields and a firmly hawkish Fed posture. The 30-year Treasury hit its highest level since 2002 (30-year mortgage at 7.58%), with the 30-year Treasury at its post-2002 peak being a mechanical risk for TMO's valuation multiple. Prediction markets price 96% odds of zero Fed cuts in 2026, with US recession odds at just 8% by year-end—suggesting a slow grind of restrictive policy rather than a hard landing. USD strength implied by US-Japan/EU rate divergence creates an FX translation headwind for TMO's 40%+ international revenue. Equity indices (Dow, S&P 500, Nasdaq) finished the week lower as bond yields climbed, with AI/tech names garnering flows while defensive healthcare/life-sciences tools lagged. Gold at ~$4,147/oz reflects investor anxiety over sovereign/term-premium risk.